• Advertise
  • About us
  • Terms and Conditions
  • Contact us
Wednesday, November 11, 2026
Australian Times News
  • News
    • Weather
    • Sport
    • Technology
    • Business & Finance
      • Currency Zone
    • Lotto Results
      • The Lott
  • Lifestyle
    • Entertainment
    • Horoscopes
    • Health & Wellness
    • Recipes
  • Travel
  • Expat Life
  • Move to Australia
No Result
View All Result
  • News
    • Weather
    • Sport
    • Technology
    • Business & Finance
      • Currency Zone
    • Lotto Results
      • The Lott
  • Lifestyle
    • Entertainment
    • Horoscopes
    • Health & Wellness
    • Recipes
  • Travel
  • Expat Life
  • Move to Australia
No Result
View All Result
Australian Times News
No Result
View All Result
Home News

How effective does a COVID-19 coronavirus vaccine need to be to stop the pandemic? A new study has answers

Similarly, different vaccines may offer different levels of protection. Scientists talk about this as the vaccine’s efficacy or effectiveness.

The Conversation by The Conversation
19-07-2020 18:09
in News
COVID-19 coronavirus vaccine

COVID-19 coronavirus Photo by Georg Eiermann on Unsplash

Bruce Y. Lee, City University of New York

The U.S. is pinning its hopes on a COVID-19 coronavirus vaccine, but will a vaccine alone be enough to stop the pandemic and allow life to return to normal?

The lower the vaccine’s effectiveness, the more likely social distancing in some form may still be necessary. Gopixa via Getty Images

The answer depends on a how “good” the vaccine ends up being.

In a study published July 15 in the American Journal of Preventive Medicine, my colleagues and I used a computer simulation of every person in the country to show how effective a vaccine would have to be and how many people would have to get vaccinated to end the pandemic. We found that a coronavirus vaccine’s effectiveness may have to be higher than 70% or even 80% before Americans can safely stop relying social distancing. By comparison, the measles vaccine has an efficacy of 95%-98%, and the flu vaccine is 20%-60%.

That doesn’t mean a vaccine that offers less protection would be useless, but it would mean social distancing in some form may still be necessary.

What is vaccine ‘effectiveness’ anyway?

Some political leaders have suggested that society will return to normal soon, especially if a vaccine becomes available by the end of the year or early in 2021. Some vaccines are currently in early-stage trials, but that timeline would still be very optimistic.

However, it is important to remember that a vaccine is like many other products: What matters is not just that the product is available but also how effective it is. Take clothing for example. If you are going to a formal dinner, underwear alone may partially cover you but probably not well enough for the occasion. This doesn’t mean underwear is useless.

AlsoRead...

How She Sells with Brooke helps thousands of women build new careers through high-ticket sales

How She Sells with Brooke helps thousands of women build new careers through high-ticket sales

6 October 2026
Mark Levin and Yael Eckstein: Celebrating 250 Years - The Bond Between America and Israel

Mark Levin and Yael Eckstein: Celebrating 250 Years – The Bond Between America and Israel

30 September 2026

Similarly, different vaccines may offer different levels of protection. Scientists talk about this as the vaccine’s efficacy or effectiveness. If 100 people who haven’t been exposed to the virus are given a vaccine that has an efficacy of 80%, that means that on average 80 of them would not get infected.

[Get our best science, health and technology stories. Sign up for The Conversation’s science newsletter.]

The difference between efficacy and effectiveness is that the former applies when vaccination is given under controlled circumstances, like a clinical trial, and the latter is under “real-world” conditions. Typically, a vaccine’s effectiveness tends to be lower than its efficacy.

Computer simulations show what could happen

Since COVID-19 coronavirus vaccines are still under development, now is the time to set vaccine efficacy levels to aim for, as well as to manage expectations. Running computer simulations is really the only way to ethically do this.

For the study, our PHICOR team at the City University of New York Graduate School of Public Health and Health Policy, working with scientists from the National School of Tropical Medicine at the Baylor College of Medicine, developed a computer simulation model of the entire United States and its population interacting with each other. Using that model, we were able to introduce the COVID-19 virus into this virtual population in different ways and have it spread from person to person in various pandemic scenarios. Each simulated person who gets infected has probabilities of being hospitalized, placed on a ventilator or dying based on the severity of the problems just as in the real world.

Experiments using this simulated population can represent the different vaccines and what is likely to happen if different proportions of the population are vaccinated at different times during the pandemic. The results show how vaccines with different levels of efficacy would affect the pandemic and can be used to estimate the impact on things such as number of people who get infected, health outcomes and costs. In this case, we assumed that only one vaccination would be required.

What will it take to stop the pandemic?

Typically, in an epidemic or pandemic, as more people are exposed to the virus, the number of new infections per day steadily increases until it reaches a peak and begins to drop. Of course, how long this takes depends upon how the virus and the response to it may evolve over time.

To stop the pandemic, the number of new infections per day needs to drop to zero, or at least to a very low number, as quickly as possible.

If the COVID-19 pandemic was just beginning and the population infected was close to 0%, the simulations show that vaccine efficacy would have to be at least 60% to stop the coronavirus if the entire population was vaccinated. Given the number of susceptible people who couldn’t be vaccinated because of age or health problems and the number who would refuse to be vaccinated, that’s probably impossible.

If only 75% of the population gets vaccinated, the vaccine efficacy would have to be around 70%. If only 60% of people get vaccinated, the threshold goes even higher, to around 80%. It’s all about making sure the virus can’t find more people to infect.

Those numbers assume that a person infected with the virus infects 2.5 other people on average. If the virus is more contagious, the vaccine has to be more efficient.

Now, the further along the pandemic is, the less the height of the peak can be reduced. It’s like climbing a mountain – you are already at a certain height. Plus, it is harder to shut a pandemic down when there are more infectious people running around.

So, when 5% of the population has already been infected with the virus, the best that you can do is reduce the peak by around 85%. The difference between 0% and 5% can add up to millions of infections. So far, about 1% of the U.S. population has been confirmed to have been infected, but officials estimate the actual percentage is much higher.

How many people get vaccinated is crucial

Based on these findings, a vaccine with an efficacy as low as 60% could still stop the pandemic and allow society to return to normal. However, most if not all of the population would have to be vaccinated.

This seems unlikely, given polls showing that only about three-quarters of Americans say they would get a coronavirus vaccine if assured that it was safe.

With fewer people protected, a vaccine would have to have an efficacy of at least 80% to be able to stop the pandemic by itself, meaning social distancing could be completely relaxed. This can provide a target to aim for when developing COVID-19 coronavirus vaccines.

Again, all of this doesn’t mean that a vaccine with a lower efficacy would not be useful. It would mean that social distancing and mask-wearing likely would have to continue until the pandemic runs its course or a vaccine that is actually “good enough” arrives.

Bruce Y. Lee, Professor of Health Policy and Management, City University of New York

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Tags: SB001
DMCA.com Protection Status

SUBSCRIBE to our NEWSLETTER

[mc4wp_form id=”2384248″]

Don't Miss

NRMA welcomes dogs at four NSW South Coast Holiday Parks

by Pauline Torongo
22 October 2026
NRMA welcomes dogs at four NSW South Coast Holiday Parks
Lifestyle

Pet-friendly stays and nearby beaches give families more coastal holiday options as Australian caravan and camping trips reach record levels.

Read moreDetails

How She Sells with Brooke helps thousands of women build new careers through high-ticket sales

by Pauline Torongo
6 October 2026
How She Sells with Brooke helps thousands of women build new careers through high-ticket sales
Business & Finance

More than 3,000 women have joined She Sells with Brooke Triplett to build careers in high-ticket sales. For many, the...

Read moreDetails

Qualities to look for in a Caribbean Luxury Cruise Experience

by Pauline Torongo
6 October 2026
Qualities to look for in a Caribbean Luxury Cruise Experience. Image: Supplied
Travel

Luxury Caribbean cruises are often associated with beaches, sunshine, and tropical ease, but they can be more than that with...

Read moreDetails

Mark Levin and Yael Eckstein: Celebrating 250 Years – The Bond Between America and Israel

by Pauline Torongo
30 September 2026
Mark Levin and Yael Eckstein: Celebrating 250 Years - The Bond Between America and Israel
News

As America marks 250 years since the Declaration of Independence, Yael Eckstein and Mark Levin explore the biblical values and...

Read moreDetails

How supporting Australia’s Care Workforce could strengthen care in the community

by Pauline Torongo
10 September 2026
How supporting Australia’s Care Workforce could strengthen care in the community
News

Australian care funding faces growing scrutiny after a 2025 ANAO report found NDIS losses from fraud, non-compliance, and payment errors...

Read moreDetails

The Future of Work Is Changing: What HR must champion next, according to Energy Collective Co

by Pauline Torongo
28 August 2026
What HR Must Champion Next, According to Energy Collective Co
Business & Finance

Energy Collective Co examines the root causes of performance by considering how work is designed, how leadership is enacted and...

Read moreDetails

From Empathy Burnout to Body-Led Recovery: What Heidi Jane of Intuition Co. learned by living through what she teaches

by Pauline Torongo
25 August 2026
What Heidi Jane of Intuition Co. learned by living through what she teaches
Lifestyle

Recognising emotional exhaustion is only the first step. While supportive habits such as rest, time in nature, hydration, and reduced...

Read moreDetails
Load More

Copyright © Blue Sky Publications Ltd. All Rights Reserved.
australiantimes.co.uk is a division of Blue Sky Publications Ltd. Reproduction without permission prohibited. DMCA.com Protection Status

  • About us
  • Write for Us
  • Advertise
  • Contact us
  • T&Cs, Privacy and GDPR
No Result
View All Result
  • News
    • Weather
    • Sport
    • Technology
    • Business & Finance
      • Currency Zone
    • Lotto Results
      • The Lott
  • Lifestyle
    • Entertainment
    • Horoscopes
    • Health & Wellness
    • Recipes
  • Travel
  • Expat Life
  • Move to Australia

Copyright © Blue Sky Publications Ltd. All Rights Reserved.
australiantimes.co.uk is a division of Blue Sky Publications Ltd. Reproduction without permission prohibited. DMCA.com Protection Status

No Result
View All Result
  • News
    • Weather
    • Sport
    • Technology
    • Business & Finance
      • Currency Zone
    • Lotto Results
      • The Lott
  • Lifestyle
    • Entertainment
    • Horoscopes
    • Health & Wellness
    • Recipes
  • Travel
  • Expat Life
  • Move to Australia

Copyright © Blue Sky Publications Ltd. All Rights Reserved.
australiantimes.co.uk is a division of Blue Sky Publications Ltd. Reproduction without permission prohibited. DMCA.com Protection Status